Teva Pharmaceutical Industries Executive Compensation (FY25)

Name: Teva Pharmaceutical Industries (TEVA) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

TEVA · Executive and director compensation, fiscal 2023 to 2025

The Teva Pharmaceutical Industries brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of September 19, 2026Latest filing (8-K): May 28, 2026

13 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Teva Pharmaceutical Industries brief$1,500Get the executive brief

273 figures on this page: 264 cited to the filing that reported them, 9 calculated from figures it prints. See the citations

Chief executive, fiscal 2025

◇

Richard Francis

Latest say-on-pay support

May 28, 2026

Chief executive pay ratio

◇

To the median employee

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Richard Francis: $15,518,947 → $19,168,709 (23.5% higher)

Say-on-pay support: 87.4% → 91.2% (3.8 points higher)

CEO pay ratio: 234:1 → 257:1 (9.8% higher)

Frequently asked questions

Answers drawn from the data on this page.

Who is Teva Pharmaceutical Industries' chief executive and what were they paid?

Richard Francis, President and Chief Executive Officer, received $19,168,709 in total compensation for fiscal 2025. Compared with the $15,518,947 reported for fiscal 2024, Francis' total was 23.5% higher.

What was Teva Pharmaceutical Industries' say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 91.2% of votes cast for or against in favor at the meeting held May 28, 2026.

What is Teva Pharmaceutical Industries' chief executive pay ratio?

The company reported a chief executive pay ratio of 257:1 for fiscal 2025, against median employee compensation of $74,725.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Richard Francis President and Chief Executive Officer	◇	◇	◇	—	◇	—	◇	◇
Eli Kalif Executive Vice President, Chief Financial Officer	◇	—	◇	—	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Richard Francis President and Chief Executive Officer	◇	◇	◇	—	◇	—	◇	◇
Eli Kalif Executive Vice President, Chief Financial Officer	◇	—	◇	—	◇	—	◇	◇
Eric Hughes Executive Vice President, Global R&D and Chief Medical Officer	◇	—	◇	—	◇	—	◇	◇
Christine Fox Executive Vice President, U.S. Commercial	◇	—	◇	—	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Richard Francis President and Chief Executive Officer	◇	—	◇	—	◇	—	◇	◇
Evan Lippman Executive Vice President, Business Development	◇	◇	◇	—	◇	—	◇	◇
Eli Kalif Executive Vice President, Chief Financial Officer	◇	—	◇	—	◇	—	◇	◇
Eric Hughes Executive Vice President, Global R&D and Chief Medical Officer	◇	—	◇	—	◇	—	◇	◇
Christine Fox Executive Vice President, U.S. Commercial	◇	—	◇	—	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Christine Fox	RSU	◇	—	—	◇	—	—	◇
Christine Fox	PSU	◇	◇	◇	◇	◇	—	◇
Eli Kalif	RSU	◇	—	—	◇	—	—	◇
Eli Kalif	PSU	◇	◇	◇	◇	◇	—	◇
Eric Hughes	RSU	◇	—	—	◇	—	—	◇
Eric Hughes	PSU	◇	◇	◇	◇	◇	—	◇
Evan Lippman	RSU	◇	—	—	◇	—	—	◇
Evan Lippman	RSU	◇	—	—	◇	—	—	◇
Evan Lippman	PSU	◇	◇	◇	◇	◇	—	◇
Richard Francis	PSU	◇	◇	◇	◇	◇	—	◇
Richard Francis	RSU	◇	—	—	◇	—	—	◇
Richard Francis	PSU	◇	◇	◇	◇	◇	—	◇
Richard Francis	RSU	◇	—	—	◇	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Eli Kalif	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Christine Fox	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
Eric Hughes	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Richard Francis	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
Evan Lippman	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Christine Fox

Executive Vice President, U.S. Commercial · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance cash amount	◇
Non-compete period	◇

Eli Kalif

Executive Vice President, Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance cash amount

◇

Eric Hughes

Executive Vice President, Global R&D and Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance cash amount	◇
Non-compete period	◇

Evan Lippman

Executive Vice President, Business Development · Employment agreement · citing a 2026 filing

Severance base	◇
Change-in-control base	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇
Clawback	◇

Richard Francis

President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance cash amount	◇
Non-compete period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Dr. Sol J. Barer Board chair	◇	◇	—	—	—	—	◇
Gerald M. Lieberman	◇	◇	—	—	—	—	◇
Roberto A. Mignone	◇	◇	—	—	—	—	◇
Janet S. Vergis	◇	◇	—	—	—	—	◇
Dr. Perry D. Nisen	◇	◇	—	—	—	—	◇
Amir Elstein	◇	◇	—	—	—	—	◇
Rosemary A. Crane	◇	◇	—	—	—	—	◇
Chen Lichtenstein	◇	◇	—	—	—	—	◇
Prof. Ronit Satchi-Fainaro	◇	◇	—	—	—	—	◇
Dr. Tal Zaks	◇	◇	—	—	—	—	◇
Prof. Varda Shalev	◇	◇	—	—	—	—	◇

Richard D. Francis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇

Equity is delivered as restricted stock units.

Stock ownership guideline: 7x annual cash fee (excluding committee fees)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Element ESI

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 28, 2026	=	◇	◇	◇
2024	June 5, 2025	=	◇	◇	◇
2023	June 6, 2024	=	◇	◇	◇
2022	June 15, 2023	=	◇	◇	◇
2021	June 23, 2022	=	◇	◇	◇
2020	June 14, 2021	=	◇	◇	◇
2019	June 9, 2020	=	◇	◇	◇
2018	June 11, 2019	=	◇	◇	◇
2017	June 5, 2018	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

What this page does not include

Everything above is a fact Teva Pharmaceutical Industries disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Teva Pharmaceutical Industries sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $1,200

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

273 figures on this page: 264 cited to the filing that reported them, 9 calculated from figures it prints.

264 cited to the filing

9 calculated from the filing

Documents cited

8-K, filed May 28, 2026
0001193125-26-245203
DEF 14A, filed March 31, 2026
0001193125-26-134756
2025 Director Compensation · 2025 Outstanding Equity Awards at Fiscal Year-End · 2025 Summary Compensation Table · Compensation Discussion and Analysis · and 3 more sections
8-K, filed June 5, 2025
0001193125-25-135942
DEF 14A, filed April 9, 2025
0001193125-25-076829
2024 Summary Compensation Table
8-K, filed June 6, 2024
0001193125-24-156043
DEF 14A, filed April 16, 2024
0001193125-24-097745
2023 Summary Compensation Table
8-K, filed June 15, 2023
0001193125-23-167868
8-K, filed June 23, 2022
0001193125-22-180042
8-K, filed June 14, 2021
0001193125-21-190033
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 9, 2020
0001193125-20-164664
8-K, filed June 11, 2019
0001193125-19-170274
8-K, filed June 6, 2018
0001193125-18-185246
Filing
0001193125-26-034532
EX-10.23

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Teva Pharmaceutical Industries executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/TEVA (accessed 2026).

Short form: data: Velarion

The Teva Pharmaceutical Industries brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

13 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/TEVA/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Teva Pharmaceutical Industries executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Teva Pharmaceutical Industries and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Peers Teva Pharmaceutical Industries discloses

The companies named in TEVA's own disclosed peer group.

Element

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}